Summary: A large genetic study has identified 956 genes linked to an increased risk of insomnia and mapped the brain regions, cell types, and biological pathways that mediate that genetic risk.
Source: VRIJE University Amsterdam.
An international research consortium has, for the first time, pinpointed the specific brain cell types, regions and biological processes that translate genetic risk into insomnia. By analyzing DNA and sleep-related data from approximately 1.3 million people, the team uncovered hundreds of genetic contributors and traced how they act in the brain. These results, published in Nature Genetics, represent a major advance toward understanding the biological mechanisms behind chronic insomnia.
Insomnia is one of the most common sleep disorders. While most people have an occasional poor night, roughly one in ten experience chronic insomnia and suffer significant daytime impairment. Globally, an estimated 770 million people are affected by chronic insomnia, with substantial public health and economic impacts.
Genetic vulnerability is rooted in brain structure and cell function
Many people with insomnia report lasting vulnerability to poor sleep even after treatment. Family and twin studies indicate a heritable component to this susceptibility, suggesting underlying biological mechanisms in the brain. Until now, only a few genetic variants and limited brain targets had been implicated. Identifying the precise cells and regions where genetic risk exerts its effects is essential to develop more effective, targeted treatments.
Unprecedented sample size and comprehensive analysis
Led by Statistical Genetics professor Danielle Posthuma (VU Amsterdam / Amsterdam UMC) and Neurophysiology professor Eus Van Someren (Netherlands Institute for Neuroscience), the international team combined data from many cohorts, including population biobanks and direct-to-consumer datasets, assembling genetic and sleep phenotype information from about 1.3 million people—the largest dataset analyzed for insomnia genetics to date.
The analysis revealed 202 genomic loci implicating a total of 956 genes associated with insomnia risk. The investigators then performed functional mapping and enrichment analyses to determine which biological processes, brain tissues and cell types use these genes. A notable subset of genes clustered in pathways related to axonal structure and function—the long projections that enable neurons to communicate—suggesting that altered neuronal connectivity or signaling contributes to insomnia vulnerability.
Specific brain regions and cell types highlighted
The researchers found enrichment of insomnia-associated genes in particular cell populations and brain regions. Several implicated genes show higher activity in specific cell types within parts of the frontal cortex and in subcortical nuclei, areas that recent neuroimaging studies have also associated with insomnia. Among the specific neuronal subtypes identified were medium spiny neurons and other striatal and subcortical cell populations. These convergent findings from genetic and imaging data strengthen the evidence for targeted brain circuits involved in insomnia.
“Insomnia is influenced by hundreds of genetic variants, each with a small effect,” says Danielle Posthuma. “Rather than focusing on single variants, looking at their combined impact reveals the cell types and pathways that matter. That allows us to begin studying underlying mechanisms in individual brain cells in the lab.” Guus Smit, a neurobiologist who contributed to the work, adds that the ability to link large-scale, global data to micro-level cellular processes is now opening new experimental avenues. Philip Jansen, the study’s first author, notes that assembling such vast datasets makes it possible to infer molecular and cellular changes that were previously out of reach.
Genetic links to psychiatric and metabolic conditions
Contrary to expectations, the study found relatively little genetic overlap between insomnia risk and genes that influence other sleep-timing traits (for example, being a morning or evening person). Instead, insomnia genetics showed strong overlap with psychiatric conditions—particularly depression and anxiety—and also shared genetic risk with metabolic disturbances linked to obesity and diabetes. These results suggest that circuits regulating emotion, stress and arousal may be central to insomnia risk, rather than circuits governing basic sleep timing.
“These findings require a shift in focus toward neural systems that regulate emotion and tension,” says Eus Van Someren. Researchers applied Mendelian randomization methods that provided evidence suggesting insomnia can have causal effects on depression, diabetes and cardiovascular disease, while higher educational attainment and larger intracranial volume appeared to have protective effects. The combined genetic evidence emphasizes that chronic insomnia is a serious condition with broad health implications.
Source: VRIJE University Amsterdam
Publisher: Organized by NeuroscienceNews.com.
Image source: Image in the public domain.
Original research: Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways — Nature Genetics (Philip R. Jansen et al.). DOI: 10.1038/s41588-018-0333-3. Published February 25, 2019.
Abstract (summary)
Using genetic data from 1,331,010 individuals, researchers identified 202 loci implicating 956 genes associated with insomnia. The discovered genes point to enrichment in axonal components, cortical and subcortical tissues, and specific neuronal cell types including striatal, hypothalamic, and claustrum neurons. Genetic correlations were strong with psychiatric traits and sleep duration and more modest with other sleep traits. Mendelian randomization highlighted potential causal links between insomnia and depression, diabetes, and cardiovascular disease, while suggesting protective effects of educational attainment and intracranial volume. These results highlight key brain areas and cell types implicated in insomnia and provide candidate targets for future treatment development.